LOGIN
Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS
March 2019
Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Sativex as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Int J Neurosci. 2018 Sep 13:1-10.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
106 patients with resistant multiple sclerosis who had demonstrated adequate treatment response to Sativex (tetrahydrocannabinol and cannabidiol oromucosal spray) treatment in a 4-week trial phase were randomized to Sativex or placebo for 12 weeks after 1-4 week washout from the trial phase. The purpose of the study was to determine if tetrahydrocannabinol and cannabidiol oromucosal spray (THC:CBD...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.